Micro- and macrovascular complications of type 2 diabetes have an adverse impact on survival, quality of life and healthcare costs. The OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) trial comparing physicians’ individual performances with a peer group evaluates the hypothesis that benchmarking, using assessments of change in three critical quality indicators of vascular risk: glycated haemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C) and systolic blood pressure (SBP), may improve quality of care in type 2 diabetes in the primary care setting.
Design:
This was a randomised, controlled study of 3980 patients with type 2 diabetes.
Methods:
Six European countries participated in the OPTIMISE study (NCT00681850). Quality of care was assessed by the percentage of patients achieving pre-set targets for the three critical quality indicators over 12 months. Physicians were randomly assigned to receive either benchmarked or non-benchmarked feedback. All physicians received feedback on six of their patients’ modifiable outcome indicators (HbA1c, fasting glycaemia, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), LDL-C and triglycerides). Physicians in the benchmarking group additionally received information on levels of control achieved for the three critical quality indicators compared with colleagues.
Results:
At baseline, the percentage of evaluable patients (N = 3980) achieving pre-set targets was 51.2% (HbA1c; n = 2028/3964); 34.9% (LDL-C; n = 1350/3865); 27.3% (systolic blood pressure; n = 911/3337).
Conclusions:
OPTIMISE confirms that target achievement in the primary care setting is suboptimal for all three critical quality indicators. This represents an unmet but modifiable need to revisit the mechanisms and management of improving care in type 2 diabetes. OPTIMISE will help to assess whether benchmarking is a useful clinical tool for improving outcomes in type 2 diabetes.
KannelWBWilsonPWZhangTJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J1991; 121: 1268–1273.
2.
OldridgeNBStumpTENothwehrFK. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol2001; 54: 928–934.
3.
HaffnerSM. Management of dyslipidemia in adults with diabetes. Diabetes Care1998; 21: 160–178.
4.
LiptonRBLiaoYCaoGCooperRS. Determinants of incident non-insulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol1993; 138: 826–839.
5.
AlexanderCMLandsmanPBTeutschSM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes2003; 52: 1210–1214.
6.
JuutilainenALehtoSRönnemaaT. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care2005; 28: 2901–2907.
7.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837–853.
8.
UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ1998; 317: 703–713.
9.
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med2005; 165: 1410–1419.
10.
PyoˇräläKPedersenTRKjekshusJ. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997; 20: 614–620.
11.
GoldbergRBMelliesMJSacksFM. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation1998; 98: 2513–2519.
12.
HaffnerSMAlexanderCMCookTJ. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med1999; 159: 2661–2667.
13.
SelvinEMarinopoulosSBerkenblitG. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med2004; 141: 421–431.
14.
StrattonIMAdlerAINeilHA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000; 321: 405–412.
15.
GersteinHCPogueJMannJF. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia2005; 48: 1749–1755.
16.
GersteinHCMillerMEByingtonRP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008; 358: 2545–2559.
17.
PatelAMacMahonSChalmersJ. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008; 358: 2560–2572.
18.
DuckworthWAbrairaCMoritzT. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med2009; 360: 129–139.
19.
RayKKSeshasaiSRWijesuriyaS. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet2009; 373: 1765–1772.
20.
HanssonLZanchettiACarruthersSG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998; 351: 1755–1762.
21.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002; 288: 2981–2997.
22.
PatelA. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007; 370: 829–840.
23.
AdlerAIStrattonIMNeilHA. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ2000; 321: 412–419.
24.
KearneyPMBlackwellLCollinsR. Cholesterol Treatment Trialists' (CTT) Collaborators; Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet2008; 371: 117–125.
25.
GaedePLund-AndersenHParvingHH. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–591.
26.
HermansMP. Prevention of microvascular diabetic complications by fenofibrate: Lessons from FIELD and ACCORD. Diab Vasc Dis Res2011; 8: 180–189.
27.
AndelMGrzeszczakWMichalekJ. A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey). Diabet Med.2008; 25: 1195–1203.
28.
HuppertzEPieperLKlotscheJ. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes2009; 117: 6–14.
29.
Benhalima K and Mathieu C. Challenges in the management of hyperglycaemia in type 2 diabetes. Background paper in IDF Diabetes Atlas 4th edition International Diabetes Federation, 2009. (http://www.idf.org/diabetesatlas/downloads/backgroundpapers).
30.
NobelsFDebackerNScheenAJ. Conseil Scientifique d'IPQED. Initiative to promote quality of care and epidemiology of diabetes mellitus. Rev Med Liege2005; 60: 624–627.
31.
DebackerNNobelsFVandenbergheH. Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience. Diabet Med2008; 25: 179–185.
32.
BodenheimerTWagnerEGrumbachK. Improving primary care for patients with chronic illness: the chronic care model. JAMA2002; 288: 1775–1779.
33.
BodenheimerTWagnerEGrumbachK. Improving primary care for patients with chronic illness. The Chronic Care Model, part 2. JAMA2002; 288: 1909–1914.
34.
BodenheimerTLorigKHolmanH. Patient self-management of chronic disease in primary care. JAMA2002; 288: 2469–2475.
35.
PlsekPE. Section 1: Evidence-based quality improvement, principles, and perspectives. Quality improvement methods in clinical medicine. Pediatrics1999; 103: E203–E214.
36.
KiefeCIAllisonJJWilliamsOD. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA2001; 285: 2871–2879.
37.
SmithSAShahNDBryantSCChristiansonTJ. Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc2008; 83: 747–757.
38.
NobelsFDebackerNBrotonsC. Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol2011; 10: 82–82.
39.
RydénLStandlEBartnikM. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J2007; 28: 88–136.
40.
American Diabetes Association. Clinical practice recommendations. Diabetes Care2007; 30: S1–S103.
41.
ManciaGDe BackerGDominiczakA. 2007 Guidelines for the Management of Arterial Hypertension. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens2007; 25: 1105–1187.
42.
EcclesMPWhittyPMSpeedC. A pragmatic cluster randomised controlled trial of a Diabetes Recall And Management system: the DREAM trial. Implement Sci2007; 2: 6–6.
43.
LachinJM. Biostatistical methods, New York: John Wiley & Sons, 2002.
Brohet C, De Backer G, Scheen AJ, et al. Belgian evaluation of screening and treatment of high-risk patients based on waist and age (Best study). Eur J Cardiac Prev Rehab 2005; 12: 280.
46.
International Diabetes Federation (IDF) Diabetes Atlas, 2011. 5th edition. http://www.idf.org/diabetesatlas/ (Accessed 26 March 2012).
47.
StamlerJVaccaroONeatonJD. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993; 16: 434–444.
48.
HarrisMI. Diabetes in America, 2nd ed. Bethesda, MD: National Diabetes Data Group, 1995.
49.
CaroJJWardAJO'BrienJA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care2002; 25: 476–481.
50.
Serrano-GilMJacobS. Engaging and empowering patients to manage their type 2 diabetes, Part 1: a knowledge, attitude, and practice gap?Adv Ther2010; 27: 321–333.
51.
SpannSJNuttingPAGalliherJM. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med2006; 4: 23–31.
52.
AndrosVEggerADuaU. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm2006; 12: 303–309.
53.
HermansMPAmoussou-GuenouKDAhnSA. The elusive type 2 diabetes individual at blood pressure control: A phenotypic study. Diabetes Metab Syndr2010; 4: 215–219.
54.
Joseph J, Svartberg J, Njølstad I, et al. Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study. Eur J Cardiovasc Prev Rehabil epub April 2011; doi: 10.1177/1741826711408147.
55.
HermansMPCastro CabezasMStrandbergT. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin2010; 26: 445–454.
BailieRSiDConnorsC. Study protocol: audit and best practice for chronic disease extension (ABCDE) Project. BMC Health Serv Res2008; 8: 184–184.
58.
HermansMPAhnSARousseauMFResidual vascular risk in T2D: the next frontier. In: ZimeringMB (eds). Recent advances in the pathogenesis, prevention and management of type 2 diabetes and its complications, Croatia: InTech, 2011, pp. 45–66.
59.
RedonJBrunnerHRFerriC. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens2008; 26: S1–S14.
60.
DiMatteoMRGiordaniPJLepperHS. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care2002; 40: 794–811.
61.
Krousel-WoodMThomasSMuntnerP. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol2004; 19: 357–362.
62.
OwenAJReteganCRockellM. Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes. Clin Exp Pharmacol Physiol2009; 36: 643–647.
63.
BrunzellJDDavidsonMFurbergCD. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care2008; 31: 811–822.
